Dural Ectopic Lymphatic Structures Accumulate During Aging and are Dysregulated in Neurodegenerative Diseases

硬脑膜异位淋巴结构在衰老过程中积聚,并在神经退行性疾病中功能失调。

阅读:1

Abstract

BACKGROUND: This study investigates the formation and role of dural ectopic lymphoid structures (ELS) in the context of aging and neurodegenerative diseases, as these structures could serve as potential mediators of neuroimmune interactions and therapeutic targets. Using mouse models of early‐onset Alzheimer's disease (EOAD), tauopathy, and Down syndrome (DS), the study examines ELS accumulation, complexity, and interactions with brain pathology to illuminate their role in disease mechanisms. METHOD: Cranial dural meninges from aged wild‐type and transgenic mice (5xFAD and APP/PS1 for EOAD, K257T/P301S for tauopathy, and Dp1Tyb for DS) were analyzed. ELS were characterized by immunofluorescence using markers such as CD45R (B cells) and CD3 (T cells). Correlations between ELS dynamics and amyloid or tau pathology were assessed. RESULT: Meningeal ELS accumulate with age in wild‐type mice, showing sex‐specific patterns. Male mice exhibited a continuous increase in ELS with age, while female mice peaked at 12 months, possibly due to age‐related estrogen decline and its immunomodulatory effects. In 5xFAD mice, ELS formation intensified with pathology, whereas APP/PS1 mice displayed reduced ELS numbers with aging. Tauopathy and DS models showed significantly fewer ELS than controls. Correlations between ELS complexity and amyloid pathology varied by model, reflecting differences in how ELS relate to amyloid burden within distinct pathological contexts. CONCLUSION: Dural ELS exhibit age‐, sex‐, and pathology‐specific dynamics, reflecting their role in CNS pathology. Their differential regulation in AD, tauopathy, and DS highlights ELS as key players in the neuroimmune interface. Future research could explore manipulating ELS formation or function to mitigate neurodegenerative processes, potentially guiding immunomodulatory therapies tailored to specific diseases or patient populations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。